Bioventus Q4 Earnings Call Highlights

Core Insights - Bioventus reported a solid Q4 performance with revenue of $158 million, reflecting a 3% increase year-over-year and a 10% organic growth after adjusting for the Advanced Rehabilitation divestiture [7][11]. - The company highlighted strong performance in Pain Treatments, which grew 15% in Q4, driven by the DUROLANE product and a shift towards single-injection therapies [4][9]. - Management provided guidance for 2026, projecting net sales of $600–610 million and adjusted EPS of $0.73–0.77, indicating expected growth in both revenue and profitability [10][21]. International Performance - International revenue remained unchanged year-over-year in Q4, but organic growth was reported at 11% for the full year, attributed to improved commercial execution and talent additions [1]. - The timing of distributor orders impacted Q4 growth, which was noted by management [1]. Restorative Therapies - Revenue in Restorative Therapies declined by 26% due to the divestiture of Advanced Rehabilitation, but organic growth was still 10%, largely driven by strong performance from the EXOGEN product [2][9]. Surgical Solutions - Surgical Solutions saw a revenue growth of 3%, with Ultrasonics facing tough comparisons against a record high from the previous year [3]. - Generator revenue in Q4 was noted as the third-highest total ever for the company, indicating a solid foundation for future growth [3]. Pain Treatments - Pain Treatments revenue advanced by 15% in Q4, with a strong emphasis on the hyaluronic acid franchise and favorable demographics for knee osteoarthritis [4]. - The performance was significantly driven by volume, with DUROLANE leading the results [4]. Financial Performance - Adjusted EBITDA for the quarter was $37 million, a 30% increase year-over-year, with an adjusted EBITDA margin of 23%, up 490 basis points from the previous year [6][11]. - The company reported a quarterly record for cash from operations at $38 million, nearly double the prior-year quarter, contributing to a full-year cash flow of nearly $75 million, a 92% increase [13][14]. Balance Sheet and Leverage - Bioventus ended the quarter with $51 million in cash and $294 million in outstanding debt, with a reduction of $29 million in debt during the quarter [15]. - The net leverage ratio declined to below 2.5x, with expectations to be well below 2x by the end of 2026 [15]. 2026 Strategy and Investments - The company plans to allocate approximately $13 million in incremental investments across growth drivers such as PNS, PRP, Ultrasonics, and international expansion [17][18]. - Management expects the combination of PNS and PRP to contribute at least 200 basis points of growth in 2026, with further acceleration anticipated in 2027 [19]. Guidance and Expectations - For 2026, management expects Q1 to be below the implied guidance range, with growth anticipated to accelerate in Q2 and the second half of the year [22]. - The company does not anticipate any additional impact from U.S. dollar fluctuations for the year [25].